We are live on
!
Find out more
Bank Julius Baer & Co Portfolio holdings
AUM
$33.2B
1-Year Est. Return
25.01%
This Fund
S&P 500
This Quarter
Est. Return
+10.19%
1 Year Est. Return
+25.01%
3 Year Est. Return
+91.4%
5 Year Est. Return
+116.23%
10 Year Est. Return
–
AUM
$18.7B
AUM Growth
+$2.61B
(+16%)
Cap. Flow
+$602M
Cap. Flow
% of AUM
3.22%
Top 10 Holdings %
Top 10 Hldgs %
36.92%
Holding
923
New
116
Increased
301
Reduced
299
Closed
97
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$123M |
| 2 |
Intuit
INTU
|
+$85.6M |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$80.2M |
| 4 |
CME Group
CME
|
+$71M |
| 5 |
PayPal
PYPL
|
+$50M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$79.7M |
| 2 |
Roper Technologies
ROP
|
+$53M |
| 3 |
Wells Fargo
WFC
|
+$44.6M |
| 4 |
EA
Electronic Arts
EA
|
+$41.3M |
| 5 |
iShares Russell 2000 ETF
IWM
|
+$33.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.31% |
| 2 | Healthcare | 15.2% |
| 3 | Financials | 12.74% |
| 4 | Communication Services | 8.59% |
| 5 | Consumer Discretionary | 8.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
751
Axsome Therapeutics
AXSM
$10.9B
| $17K | ﹤0.01% |
+450
| New | +$16.6K |
|
|
BCLI
752
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $17K | ﹤0.01% |
278
| – | – |
|
753
Flux Power
FLUX
$11.4M
| $17K | ﹤0.01% |
+4,000
| New | +$21.3K |
|
|
DFTX
754
Definium Therapeutics
DFTX
$6.12B
| $17K | ﹤0.01% |
+837
| New | +$26.7K |
|
755
Protolabs
PRLB
$2.13B
| $17K | ﹤0.01% |
+339
| New | +$20K |
|
|
FLNA
756
Filana Therapeutics
FLNA
$48.1M
| $17K | ﹤0.01% |
+400
| New | +$21K |
|
757
VTEX
VTEX
$713M
| $17K | ﹤0.01% |
+1,600
| New | +$25.1K |
|
|
MYOV
758
DELISTED
Myovant Sciences Ltd.
MYOV
| $17K | ﹤0.01% |
1,080
| – | – |
|
759
Packaging Corp of America
PKG
$22.8B
| $16K | ﹤0.01% |
118
-3
| -2% | -$404 |
|
760
Phillips 66
PSX
$81.4B
| $16K | ﹤0.01% |
223
-2,400
| -91% | -$181K |
|
761
STAAR Surgical
STAA
$1.21B
| $16K | ﹤0.01% |
+180
| New | +$19.3K |
|
|
VXRT
762
DELISTED
Vaxart
VXRT
| $16K | ﹤0.01% |
2,500
-26,000
| -91% | -$178K |
|
763
Asana
ASAN
$2.13B
| $15K | ﹤0.01% |
+200
| New | +$21.2K |
|
764
Compass Minerals
CMP
$1.15B
| $15K | ﹤0.01% |
300
| – | – |
|
765
Nu Holdings
NU
$66.9B
| $15K | ﹤0.01% |
+1,600
| New | +$15.7K |
|
766
NovoCure
NVCR
$1.91B
| $15K | ﹤0.01% |
200
+50
| +33% | +$5.02K |
|
767
10x Genomics
TXG
$6.61B
| $15K | ﹤0.01% |
100
| – | – |
|
768
Aldeyra Therapeutics
ALDX
$93.5M
| $14K | ﹤0.01% |
3,500
| – | – |
|
769
Pan American Silver
PAAS
$21.6B
| $14K | ﹤0.01% |
579
+265
| +84% | +$6.67K |
|
770
T-Mobile US
TMUS
$190B
| $14K | ﹤0.01% |
+122
| New | +$14.4K |
|
|
AMRN
771
Amarin Corp
AMRN
$303M
| $13K | ﹤0.01% |
200
| – | – |
|
772
Bloom Energy
BE
$64.6B
| $13K | ﹤0.01% |
600
-15,319
| -96% | -$387K |
|
773
On Holding
ONON
$12.5B
| $13K | ﹤0.01% |
350
-1,378
| -80% | -$50.6K |
|
|
SLI
774
Standard Lithium
SLI
$584M
| $13K | ﹤0.01% |
1,358
+871
| +179% | +$8.53K |
|
775
NXP Semiconductors
NXPI
$60.4B
| $12K | ﹤0.01% |
51
-252
| -83% | -$53.6K |
|
Similar funds
PPF
GAM
VIA
Bank Julius Baer & Co's Q4 2021 Portfolio in Review
As of Q4 2021, Bank Julius Baer & Co held 923 positions worth $18.7B, up 16% from $16.1B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Bank Julius Baer & Co deployed $602M of net new capital in Q4 2021, opening 116 new positions and adding to 301 existing holdings. Its largest new stake was iShares US Treasury Bond ETF: 785,741 shares worth $21M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Merck, an estimated $79.7M trimmed.
- Bank Julius Baer & Co's largest Q4 2021 buy was iShares US Treasury Bond ETF: 785,741 shares worth $21M.
- Bank Julius Baer & Co added most to State Street SPDR S&P 500 ETF Trust in Q4 2021, an estimated $123M increase.
- Bank Julius Baer & Co's biggest Q4 2021 reduction was Merck, cutting an estimated $79.7M.
- Bank Julius Baer & Co fully exited Encompass Health in Q4 2021, selling an estimated $32.7M.
- Bank Julius Baer & Co's ten largest holdings make up 37% of its $18.7B portfolio in Q4 2021.
- Bank Julius Baer & Co opened 116 new positions and closed 97 in Q4 2021.
- Bank Julius Baer & Co's portfolio value rose 16% quarter-over-quarter to $18.7B.
Based on Bank Julius Baer & Co's 13F filing for Q4 2021, filed 15 Feb 2022.